JAK inhibitors and uses thereof
The present invention provides methods for treating pruritus in a subject in need thereof comprising administering a therapeutically effective amount of a JAK inhibitor. Also provided are methods of intranasal administration of JAK inhibitors for use in treating pruritus.
1. A method for treating pruritus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a JAK1 inhibitor.
2. The method of claim 1 , wherein the subject is diagnosed with pruritus or chronic idiopathic pruritus and treatment prevents or reduces pruritus in the subject.
3. The method of claim 1 , wherein the subject has
extremely severe itching or severe itching; or
the subject has moderate or mild itching.
4. The method of claim 1 , wherein
the pruritus has lasted for at least at least seven weeks;
the pruritus has lasted for at least at least eight weeks;
the pruritus has lasted for at least at least nine weeks; or
the pruritus has lasted for at least at least ten weeks.
5. The method of claim 1 , wherein treatment reduces severity of itching in a subject, increases number of itch-free days in the subject, improves quality of life of the subject, or any combination thereof.
6. The method of claim 1 , wherein the subject is predisposed to pruritus or chronic idiopathic pruritus and treatment with the JAK inhibitor prevents a reoccurrence of chronic pruritus in the subject or reduces frequency of acute pruritus in the subject.
7. The method of claim 1 , wherein the JAK inhibitor is selected from one or more of the group consisting of: tofacitinib, ruxolitinib, baricitinib, itacitnib (INCB039110), oclacitinib, AZD1480, fedratinib, AT9283, AG-490, momelotinib, TG101209, gandotinib, NVP-BSK805, AZ 960, CEP-33779, Pacritinib, XL019, S-Ruxolitinib, ZM 39923, Decernotinib, Cerdulatinib, filgotinib, FLLL32, BMS-911543, peficitinib, GLPG0634, GLPG0634 analogue, Go6976, curcumol, cucurbitacin, lestaurtinib, upadacitinib, CHZ868, Solcitinib (GSK 2586184), NS-018; or a derivative thereof; or pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the JAK inhibitor is
or a combination thereof.
9. The method of claim 1 , where the JAK inhibitor is administered parenterally, intrathecally, intranasally, or orally.
10. The method of claim 1 , wherein the JAK inhibitor is administered on a daily basis, administered on a daily basis for at least 7 consecutive days, at least 14 consecutive days, or at least 30 consecutive days.
11. The method of claim 1 , wherein the pruritus is a symptom of broad activation of immune responses or dysregulation of neuronal processes and sensory perception.
12. The method of claim 1 , wherein the subject is diagnosed with, or the pruritus is a symptom of, a disease or condition selected from one or more of the group consisting of: allergic reaction, arthropod bites, athlete's foot, atopic dermatitis (AD), atopic itch, atopic dermatitis-associated itch, autoimmune connective tissue disease, bacterial infection, biliary itch, broad activation of immune responses, body louse, bullous diseases, brachioradial pruritus, brain tumors, chronic idiopathic pruritus, contact dermatitis, cholestasis, cutaneous larva migrans, cutaneous T-cell lymphoma, nervous system damage, dandruff, delusional parasitosis, dermatomyositis, dermatosis of pregnancy, diabetes mellitus, drug eruptions, dysregulation of neuronal processes and sensory perception, eczema, eosinophilic folliculitis, foreign objects or devices on skin, fungal infection, gestational pemphigoid, head lice, herpes, hidradenitis suppurativa, hives, Hodgkin's disease, hyperparathyroidism, idiopathic chronic itch, inflammation, insect infestation, insect bites, insect stings, intrahepatic cholestasis of pregnancy, iron deficiency anemia, increased accumulation of exogenous opioids or synthetic opioids, internal cancer, jaundice, lichen planus, lichen sclerosus, lupus erythematosus, lymphoma, lymphoma-associated itch, leukemia-associated itch, malignancy, mastocytosis, menopause, multiple sclerosis, neoplasm, nerve irritation, neurogenic itch, neuropathic itch, notalgia paresthetica, notalgia obsessive-compulsive disorders, paresthetica, parasitic infection, papular urtcaria, pediculosis, peripheral neuropathy, photodermatitis, polycythemia vera, psychiatric disease, psychogenic itch, pruritic popular eruption of HIV, pruritic urticarial papules and plaques of pregnancy (PUPPP), psoriasis, psoriasis-associated itch, psoriatic itch, pubic lice, punctate palmoplantar keratoderma, renal itch, rheumatoid arthritis, scabies, scar growth, shaving, seborrheic dermatitis, stasis dermatitis, sunburn, swimmer's itch, systemic immune senescence, tactile hallucinations, Th17-associated inflammation, thyroid illness, uraemia, pruritus or uremic itch, urticaria, urticarial itch, varicella, viral infection, wound or scab healing, and xerosis.
13. The method of claim 1 , wherein
the pruritus has an inflammatory etiology;
the pruritus has neuronal dysfunction etiology; or
the pruritus has an unknown etiology.
14. The method of claim 1 , wherein the JAK inhibitor is
a TRPV1 inhibitor;
modulates signaling of IL-4 or IL-13 pathway; or
targets an IL-4Ra signaling pathway.
15. The method of claim 1 , further comprising administration of a TRPV1 inhibitor, dupilumab, or secukinumab.
16. The method of claim 1 , wherein the pruritus is chronic idiopathic pruritus.
17. The method of claim 16 , wherein the JAK inhibitor is selected from Tofacitinib or Ruxolitinib or a combination thereof.
18. The method of claim 16 , wherein the JAK inhibitor is not oclacitinib.
19. A method of treating chronic idiopathic pruritus in a human subject comprising administering to the subject a therapeutically effective amount of a JAK inhibitor selected from the group consisting of Tofacitinib and Ruxolitinib or a combination thereof.
20. The method of claim 1 , wherein the pruritus is not associated with atopic dermatitis.
21. The method of claim 1 , wherein the pruritus comprises a neurogenic itch component.